|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liao N: HER2-positive breast cancer, how
far away from the cure? On the current situation of anti-HER2
therapy in breast cancer treatment and survival of patients. Chin
Clin Oncol. 5:412016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Harbeck N: Advances in targeting
HER2-positive breast cancer. Curr Opin Obstet Gynecol. 30:55–59.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gianni L, Eiermann W, Semiglazov V, Lluch
A, Tjulandin S, Zambetti M, Moliterni A, Vazquez F, Byakhov MJ,
Lichinitser M, et al: Neoadjuvant and adju-vant trastuzumab in
patients with HER2-positive locally advanced breast cancer (NOAH):
Follow-up of a randomised controlled superiority trial with a
parallel HER2-negative cohort. Lancet Oncol. 15:640–647. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhou P, Jiang YZ, Hu X, Sun W, Liu YR, Liu
F, Luo RC and Shao ZM: Clinicopathological characteristics of
patients with HER2-positive breast cancer and the efficacy of
trastuzumab in the People's Republic of China. Onco Targets Ther.
9:2287–2295. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wong H, Leung R, Kwong A, Chiu J, Liang R,
Swanton C and Yau T: Integrating molecular mechanisms and clinical
evidence in the management of trastuzumab resistant or refractory
Her-2(+) metastatic breast cancer. Oncologist. 16:1535–1546. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pollak M: The insulin and insulin-like
growth factor receptor family in neoplasia: An update. Nat Rev
Cancer. 12:159–169. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hankins GR, De Souza AT, Bentley RC, Patel
MR, Marks JR, Iglehart JD and Jirtle RL: M6P/IGF2 receptor: A
candidate breast tumor suppressor gene. Oncogene. 12:2003–2009.
1996.PubMed/NCBI
|
|
9
|
Joung JK and Sander JD: TALENs: A widely
applicable technology for targeted genome editing. Nat Rev Mol Cell
Biol. 14:49–55. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ruan J, Li H, Xu K, Wu T, Wei J, Zhou R,
Liu Z, Mu Y, Yang S, Ouyang H, et al: Highly efficient
CRISPR/Cas9-mediated transgene knockin at the H11 locus in pigs.
Sci Rep. 5:142532015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Oceguera-Yanez F, Kim SI, Matsumoto T, Tan
GW, Xiang L, Hatani T, Kondo T, Ikeya M, Yoshida Y, Inoue H and
Woltjen K: Engineering the AAVS1 locus for consistent and scalable
transgene expression in human iPSCs and their differentiated
derivatives. Methods. 101:43–55. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Davis JM, Pennington JE, Kubler AM and
Conscience JF: A simple, single-step technique for selecting and
cloning hybridomas for the production of monoclonal antibodies.
Immunol Methods. 50:161–171. 1982. View Article : Google Scholar
|
|
13
|
Mao SJ and France DS: Enhancement of
limiting dilution in cloning mouse myeloma-spleen hybridomas by
human low density lipoproteins. J Immunol Methods. 75:309–316.
1984. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Iwamoto KS and Barber CL:
Radiation-induced posttranscriptional control of M6P/IGF2r
expression in breast cancer cell lines. Mol Carcinog. 46:497–502.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
O'Gorman DB, Weiss J, Hettiaratchi A,
Firth SM and Scott CD: Insulin-like growth factor-II/mannose
6-phosphate receptor overexpression reduces growth of
choriocarcinoma cells in vitro and in vivo. Endocrinology.
143:4287–4294. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
O'Gorman DB, Costello M, Weiss J, Firth SM
and Scott CD: Decreased insulin-like growth factor-II/mannose
6-phosphate receptor expression enhances tumorigenicity in JEG-3
cells. Cancer Res. 59:5692–5694. 1999.PubMed/NCBI
|
|
17
|
Lee JS, Weiss J, Martin JL and Scott CD:
Increased expression of the mannose 6-phosphate/insulin-like growth
factor-II receptor in breast cancer cells alters tumorigenic
properties in vitro and in vivo. Int J Cancer. 107:564–570. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Souza RF, Wang S, Thakar M, Smolinski KN,
Yin J, Zou TT, Kong D, Abraham JM, Toretsky JA and Meltzer SJ:
Expression of the wild-type insulin-like growth factor II receptor
gene suppresses growth and causes death in colorectal carcinoma
cells. Oncogene. 18:4063–4068. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Devi GR, De Souza AT, Byrd JC, Jirtle RL
and Macdonald RG: Altered ligand binding insulin-like growth
facter2/mannose 6-phosphate receptor bearing missense mutations in
human cancers. Cancer Res. 59:4314–4319. 1999.PubMed/NCBI
|
|
20
|
Haisa M: The type 1 insulin-like growth
factor receptor signalling system and targeted tyrosine kinase
inhibition in cancer. J Int Med Res. 41:253–264. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pian L, Wen X, Kang L, Li Z, Nie Y, Du Z,
Yu D, Zhou L, Jia L, Chen N, et al: Targeting the IGF 1R pathway in
breast cancer using antisense inc RNA-mediated promoter cis
competition. Mol Ther Nucleic Acids. 12:105–117. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Holliday DL and Speirs V: Choosing the
right cell line for breast cancer research. Breast Cancer Res.
13:2152011. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hussain W, Mahmood T, Hussain J, Ali N,
Shah T, Qayyum S and Khan I: CRISPR/Cas system: A game changing
genome editing technology, to treat human genetic diseases. Gene.
685:70–75. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
van Diemen FR, Kruse EM, Hooykaas MJ,
Bruggeling CE, Schürch AC, van Ham PM, Imhof SM, Nijhuis M, Wiertz
EJ and Lebbink RJ: CRISPR/Cas9-mediated genome editing of
herpesviruses limits productive and latent infections. PLoS Pathog.
12:e10057012016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ophinni Y, Inoue M, Kotaki T and Kameoka
M: CRISPR/Cas9 system targeting regulatory genes of HIV-1 inhibits
viral replication in infected T-cell cultures. Sci Rep. 8:77842018.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Feng YZ, Zhang QY, Fu MT, Zhang ZF, Wei M,
Zhou JY and Shi R: Low expression of PinX1 is associated with
malignant behavior in basal-like breast cancer. Oncol Rep.
38:109–119. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mei Y, Cai D and Dai X: Modulating cancer
stemness provides luminal a breast cancer cells with HER2
positive-like features. J Cancer. 11:1162–1169. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mali P, Yang L, Esvelt KM, Aach J, Guell
M, DiCarlo JE, Norville JE and Church GM: RNA-guided human genome
engineering via Cas9. Science. 339:823–826. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yoon DS, Kim YH, Jung HS, Paik S and Lee
JW: Importance of Sox2 in maintenance of cell proliferation and
multipotency of mesenchymal stem cells in low-density culture. Cell
Prolif. 44:428–440. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Teh CZ, Wong E and Lee CY: Generation of
monoclonal antibodies to human chorionic gonadotropin by a facile
cloning procedure. J Appl Biochem. 6:48–55. 1984.PubMed/NCBI
|
